Ipca Laboratories Ltd. (NSE: IPCA) and BioSimilar Sciences PR LLC (BSS) today announced a definitive Technology Transfer and Joint Development Agreement. As part of the deal, the late-stage development, clinical manufacturing, and commercial supply of Ipca’s next-generation anti-cancer and anti-inflammatory monoclonal antibody biosimilar will move to BSS’s 200,000-square-foot sterile facility in Aguadilla, Puerto Rico.
This partnership is expected to accelerate the development and availability of the biosimilar, leveraging BSS’s advanced infrastructure and expertise in biologics manufacturing.
Robert J. Salcedo, Co-Founder & CEO, BSS, stated, “We’re turning decades of Indian innovation into American manufacturing muscle, exactly the sort of on-shoring that boosts the economy and puts life-saving biologies within reach of U.S. patients. This deal leverages BSS scientific capability while utilizing OcyonBio’s sterile filling capacity.”
Pranay Godha, Ml) & CEO, Ipca Laboratories, shared “By pairing Ipca’s established science with Puerto Rico’s skilled workforce and BSS’s regulatory expertise, we’re accelerating affordable biologies for people battling cancer and autoimmune disease worldwide.”
